GSK pay big money for cancer targets

摘要

Oxford BioTherapeutics (OBT) has formed a partnership with GiaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibod-ies through to clinical proof of concept, at which point GSK will have an exclusive option to license this monoclonal anti-body and gain responsibility for further clinical development and commercialisation.